STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.
The Danish pharma giant said it expects sales to decrease in the range of 5% to 13% in 2026, more than the 3% decrease forecasted by analysts surveyed by Visible Alpha. Novo also expects operating profits to decrease in the range of 5% to 13%, while analysts predicted a 5% decrease.
Shares of Novo plummeted more than 14% as of midday Tuesday. The company was scheduled to report earnings on Wednesday but released these results early.
Elaine Chen
Go to statnews